热门资讯> 正文
Candel Therapeutics因其胰腺癌治疗获得FDA孤儿药指定
2024-04-11 21:18
- Candel Therapeutics (NASDAQ:CADL) announced that the U.S. FDA has granted Orphan Drug Designation to CAN-2409, Candel’s most advanced multimodal biological immunotherapy candidate, for the treatment of pancreatic cancer.
- Earlier this month, Candel reported updated overall survival data from the ongoing randomized phase 2 clinical trial, where data showed notable improvement in estimated median overall survival of 28.8 months after experimental treatment with CAN-2409.
- Source: Press Release
More on Candel Therapeutics
- Candel stock soars on positive data from mid-stage pancreatic cancer drug trial
- Krystal Biotech, Candel, Edgewise gain after FDA fast track tags
- Seeking Alpha’s Quant Rating on Candel Therapeutics
- Historical earnings data for Candel Therapeutics
- Financial information for Candel Therapeutics
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
